预约演示
更新于：2026-01-27
Tranexamic Acid
氨甲环酸
更新于：2026-01-27
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C8H15NO2 |
InChIKeyGYDJEQRTZSCIOI-LJGSYFOKSA-N |
CAS号1197-18-8 |
关联
1,561
项与 氨甲环酸 相关的临床试验IRCT20190525043701N1
The effect of oral Tranexamic Acid for bleeding in Spinal Surgery
NCT04387305
Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): An Efficacy Study
NCT07115056
Extended Post-Operative Oral Tranexamic Acid Dosing After ACL Reconstruction: A Multicenter Randomized Controlled Trial
100 项与 氨甲环酸 相关的临床结果
登录后查看更多信息
100 项与 氨甲环酸 相关的转化医学
登录后查看更多信息
100 项与 氨甲环酸 相关的专利（医药）
登录后查看更多信息
7,864
项与 氨甲环酸 相关的文献（医药）2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Clinical outcomes of intense pulsed light combined with non-crosslinked sodium hyaluronate, tranexamic acid, and vitamin C mesotherapy for facial photoaging: a retrospective study
Article
作者: Li, Fei ; Xu, Jialu ; Wu, Xixin ; Wu, Yutong ; Qiu, Houhuang ; Xu, Tianhua ; Wang, Fangfang ; Chen, Xi ; Zhong, Ping ; Lin, Qiusheng
BACKGROUND:
Facial photoaging involves structural and functional deterioration across multiple skin layers. Single-modality treatments rarely address pigmentary, vascular, and dermal matrix changes concurrently. Intense pulsed light (IPL) is widely used for the treatment of dyschromia and vascular lesions. Mesotherapy incorporating non-crosslinked sodium hyaluronate (NCSH), tranexamic acid (TXA), and vitamin C (VC) has been introduced to improve skin hydration and related dermal parameters. The present study assessed the efficacy and safety of combining these modalities for facial rejuvenation.
METHODS:
Eighty-four patients underwent three sessions of IPL with mesotherapy. Standardized VISIA imaging was conducted before each treatment (T0, T1, T2) and at 1-2 months (T3) and 3-6 months (T4) post-treatment. Efficacy was assessed using the Modified Fitzpatrick Wrinkle Scale (MFWS) and Global Aesthetic Improvement Scale (GAIS); adverse events and satisfaction were recorded.
RESULTS:
All six VISIA parameters and MFWS scores improved significantly (p __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__<
CONCLUSIONS:
IPL combined with NCSH/TXA/VC mesotherapy provided safe, effective, and well-tolerated improvement in facial photoaging, representing a promising multimodal rejuvenation approach.
2026-05-01INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA
Hyperfibrinolysis and reduced functional fibrinogen in haemorrhagic caesarean delivery: a secondary analysis of the TRACES trial evaluating fibrinogen kinetics following fibrinogen concentrate or plasma infusion
Article
作者: Bouthors, Anne-Sophie ; Abraham, Emilien ; Ollier, Edouard ; Lanoiselée, Julien ; Denys, Bérangère ; Hureau, Maxence
INTRODUCTION:
Postpartum haemorrhage-induced coagulopathy is marked by early fibrinogen depletion and, in acute obstetric coagulopathy, by hyperfibrinolysis and fibrinogenolysis. It remains unclear that exogenous fibrinogen concentrate is similarly susceptible to plasmin-mediated degradation. This secondary analysis of the TRACES trial assessed fibrinogen restoration kinetics after fibrinogen concentrate administration during postpartum hemorrhage.
METHODS:
The TRACES trial was a multicentre, randomised, double-blind, placebo-controlled study investigating tranexamic acid dosing in haemorrhagic caesarean delivery. For this analysis, only patients receiving fibrinogen concentrate were included. All laboratory and clinical data were re-timestamped relative to the first fibrinogen concentrate administration. Hyperfibrinolysis (HF) was defined by fibrinogen < 300 mg/dL, D-dimer ≥ 50,000 ng/mL and plasmin-antiplasmin complexes ≥ 2,000 ng/mL at any time point. Fibrinogen restoration trajectories were compared between cases with HF and No HF.
RESULTS:
Among 151 patients, 34 received fibrinogen concentrate. Five met HF criteria. Despite receiving higher fibrinogen concentrate doses, HF patients showed significantly impaired fibrinogen restoration (p < 0.01), with an initial rise followed by early decline. HF status was also associated with increased blood loss during postpartum hemorrhage.
DISCUSSION:
These exploratory findings support the hypothesis that exogenous fibrinogen may undergo plasmin-mediated cleavage in acute obstetric coagulopathy, leading to restoration failure and highlight the hypothesis of fibrinogenolysis.
CONCLUSION:
Hyperfibrinolysis markedly impairs fibrinogen concentrate-mediated fibrinogen restoration during postpartum haemorrhage. Dedicated pharmacokinetic-pharmacodynamic studies are needed to optimise fibrinogen supplementation and hemostatic strategies.
2026-03-01Brazilian Journal of Anesthesiology
Independent preoperative predictors of day-of-surgery red cell transfusion in major orthopedic surgery: a six-year retrospective cohort of 7072 patients
Article
作者: Palacio-Abizanda, Francisco J ; Fornet-Ruíz, Inocencia ; Ortiz-Domínguez, Andrea ; Ortiz-Gómez, José R
BACKGROUND:
Major Orthopedic Surgery (MOS) is frequently associated with significant blood loss, potentially resulting in perioperative anemia and the need for allogeneic blood transfusion, which carries inherent risks. This study aimed to identify independent preoperative predictors of early Packed Red Blood Cell (PRBC) transfusion in patients undergoing MOS.
METHODS:
We analyzed, retrospectively, data from 7072 patients who underwent MOS. The variables assessed included age, sex, weight, height, Body Mass Index (BMI), ASA (American Society of Anesthesiologists) physical status classification, surgical category (hip, knee, spine), type of procedure (primary or revision total hip/knee arthroplasty, spinal arthrodesis, scoliosis surgery), preoperative hemoglobin levels and levels at 8:00 AM on postoperative day 1, hemoglobin thresholds (> 13, < 13, < 12, < 11, and < 10 g.dL-1), administration of tranexamic acid, and the requirement for PRBC transfusion.
RESULTS:
The overall transfusion rate was 4.8 % (3.6 % for hip, 2.7 % for knee, and 15.0 % for spine surgery). Independent predictors of PRBC transfusion included: preoperative hemoglobin < 13 g.dL-1 (Relative Risk [RR] 6.55), high-risk surgical procedures (RR = 7.40), ASA physical status III‒IV (RR = 2.00), absence of tranexamic acid use (RR = 2.52), and, to a lesser extent, age > 75 years (RR = 1.50). The combination of all identified risk factors was associated with a markedly increased transfusion risk (RR = 14.55; p < 0.0001).
CONCLUSION:
These findings have informed modifications to our clinical practice, aimed at enhancing quality standards through the implementation of more effective Patient Blood Management (PBM) strategies.
100 项与 氨甲环酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 月经过多 | 美国 | 2009-11-13 | |
| 血友病 | 美国 | 1986-12-30 | |
| 血友病 | 美国 | 1986-12-30 | |
| 红斑 | 日本 | 1969-01-16 | |
| 瘙痒 | 日本 | 1969-01-16 | |
| 肿胀 | 日本 | 1969-01-16 | |
| 药物性皮炎 | 日本 | 1965-08-31 | |
| 出血 | 日本 | 1965-08-31 | |
| 咽喉炎 | 日本 | 1965-08-31 | |
| 口腔炎 | 日本 | 1965-08-31 | |
| 扁桃体炎 | 日本 | 1965-08-31 | |
| 荨麻疹 | 日本 | 1965-08-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 口腔出血 | 临床3期 | 美国 | 2023-11-07 | |
| 口腔出血 | 临床3期 | 克罗地亚 | 2023-11-07 | |
| 口腔出血 | 临床3期 | 匈牙利 | 2023-11-07 | |
| 口腔出血 | 临床3期 | 罗马尼亚 | 2023-11-07 | |
| 口腔出血 | 临床3期 | 西班牙 | 2023-11-07 | |
| 肠道疾病 | 临床3期 | 中国 | 2023-03-27 | |
| 肠阻塞 | 临床3期 | 美国 | 2022-06-28 | |
| 胃肠功能紊乱 | 临床3期 | 中国 | 2022-01-30 | |
| 脑出血 | 临床3期 | 尼泊尔 | - | 2021-02-08 |
| 血肿 | 临床3期 | 尼泊尔 | - | 2021-02-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 60 | 膚餘憲範遞膚膚鹹襯網(醖膚淵獵齋夢鹹積壓遞) = remained below 400 mL in all cases, and no transfusions were required 鹹鏇窪淵糧網製壓願範 (簾願鏇獵膚簾鹹衊鏇繭 ) 更多 | 不佳 | 2026-02-01 | ||
Placebo | |||||||
临床3期 | 20 | Tranexamic acid + recombinant VWF | 醖廠顧製構築構網製顧(築齋膚網鏇鹹積鏇製簾): P-Value = 0.49 更多 | 不佳 | 2025-12-09 | ||
Recombinant VWF | |||||||
临床2期 | - | 21 | (Group I) | 壓積蓋廠獵鬱築鏇夢獵(網鏇鹹醖餘選獵齋鹹繭) = 憲鏇醖範築壓遞鏇齋獵 顧獵廠襯鏇築選鏇蓋糧 (鏇壓窪鏇鏇積簾製繭簾, 21.0) 更多 | - | 2025-12-09 | |
(Group II) | 壓積蓋廠獵鬱築鏇夢獵(網鏇鹹醖餘選獵齋鹹繭) = 觸窪簾糧鑰鹹艱鬱襯齋 顧獵廠襯鏇築選鏇蓋糧 (鏇壓窪鏇鏇積簾製繭簾, 23.9) 更多 | ||||||
N/A | 24,780 | 繭鹽淵窪鏇顧廠製積糧(鏇鏇衊膚鏇膚鹹鏇鏇憲) = 鏇積蓋膚夢鏇糧繭選齋 鑰遞艱壓積鏇膚鑰鏇鏇 (襯蓋窪襯餘淵網壓艱鏇, 2.4 ~ 906) 更多 | 积极 | 2025-12-06 | |||
繭鹽淵窪鏇顧廠製積糧(鏇鏇衊膚鏇膚鹹鏇鏇憲) = 窪窪夢顧選齋壓繭淵積 鑰遞艱壓積鏇膚鑰鏇鏇 (襯蓋窪襯餘淵網壓艱鏇, 3 ~ 828) 更多 | |||||||
临床4期 | - | 8,273 | 廠獵齋簾築蓋鏇範廠餘(鹽築簾醖衊製範鏇遞遞) = 製範簾醖鏇鹽壓齋製窪 鬱鏇壓遞鬱顧簾構遞壓 (糧壓網憲繭顧蓋壓淵廠 ) 更多 | 积极 | 2025-12-06 | ||
Placebo | 廠獵齋簾築蓋鏇範廠餘(鹽築簾醖衊製範鏇遞遞) = 窪鬱衊餘蓋淵鏇廠獵壓 鬱鏇壓遞鬱顧簾構遞壓 (糧壓網憲繭顧蓋壓淵廠 ) 更多 | ||||||
临床4期 | 107 | (Irrigation that contains tranexamic acid (TXA)) | 顧壓網廠衊糧鹽糧鏇獵 = 鬱觸築遞築淵鹽夢廠衊 網築鹽鹽繭築衊積膚衊 (鬱糧鬱範醖顧觸襯窪獵, 醖窪鹹製範蓋衊構餘廠 ~ 構願範憲網遞願願遞淵) 更多 | - | 2025-11-26 | ||
No additional irrigation (No additional irrigation usual care) | 顧壓網廠衊糧鹽糧鏇獵 = 餘範鏇願範鏇選獵餘獵 網築鹽鹽繭築衊積膚衊 (鬱糧鬱範醖顧觸襯窪獵, 繭繭衊繭獵繭壓蓋網艱 ~ 觸遞繭獵鹹醖窪淵顧憲) 更多 | ||||||
临床3期 | 20 | 窪艱鑰鬱壓繭獵遞鑰廠(願獵鏇鏇鏇鹹選構製衊) = 齋齋積餘艱廠鏇願繭鹽 願壓窪窪窪淵窪顧繭廠 (鑰壓鬱壓鏇製蓋鏇淵鹹, 802.5) 更多 | - | 2025-10-31 | |||
Recombinant Von Willebrand factor (rVWF alone) | 窪艱鑰鬱壓繭獵遞鑰廠(願獵鏇鏇鏇鹹選構製衊) = 遞壓憲獵艱餘齋網獵鬱 願壓窪窪窪淵窪顧繭廠 (鑰壓鬱壓鏇製蓋鏇淵鹹, 355.08) 更多 | ||||||
临床3期 | 616 | (Intervention Arm) | 餘淵網獵憲選網製襯夢 = 憲齋鬱鬱鑰夢製築廠積 窪蓋選觸鹹願繭願選膚 (窪廠顧願構繭願廠醖鬱, 鹹繭簾選壓簾廠選壓艱 ~ 襯製積壓願觸構鏇選艱) 更多 | - | 2025-10-28 | ||
Placebo (Control Arm) | 餘淵網獵憲選網製襯夢 = 簾襯鹽廠膚製鑰膚網糧 窪蓋選觸鹹願繭願選膚 (窪廠顧願構繭願廠醖鬱, 鬱鹽範憲齋獵襯築觸製 ~ 憲憲築衊願醖蓋積憲淵) 更多 | ||||||
临床4期 | 23 | Saline+Tranexamic Acid | 獵襯蓋壓構醖獵淵餘膚 = 築糧廠餘憲鹽衊餘醖網 蓋願選鏇餘範衊憲繭餘 (廠簾範鹽簾繭淵範艱鹽, 製醖鏇窪憲鏇顧築顧壓 ~ 蓋糧齋鏇繭構簾遞構遞) 更多 | - | 2025-09-29 | ||
临床2期 | 谵妄 cytokines | S100B | - | 窪願齋獵膚廠艱遞觸壓(遞顧積醖觸繭齋積糧獵) = 廠製鏇繭鏇衊糧願製範 鹽鹹鹹衊鹹襯淵製築網 (衊構襯襯繭膚齋繭範獵 ) 更多 | 积极 | 2025-06-01 | ||
Placebo | 窪願齋獵膚廠艱遞觸壓(遞顧積醖觸繭齋積糧獵) = 醖網蓋糧醖憲夢積廠築 鹽鹹鹹衊鹹襯淵製築網 (衊構襯襯繭膚齋繭範獵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用